Overview

A Randomized Controlled Study of Suizenji in Patients With Unresectable Pancreatic Cancer

Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel High Intensity Focused Ultrasound device (Code: Suizenji) with or with out of standard chemotherapy in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy.
Phase:
N/A
Details
Lead Sponsor:
SONIRE Therapeutics Inc.